

### IN THE CLAIMS

Please add the following claims:

86. (New) A method for the treatment of osteomyelitis comprising:  
administering a composition comprising a ligand-complexed radionuclide to a subject suffering from osteomyelitis under conditions such that said osteomyelitis is reduced.
87. (New) The method of claim 1 wherein the ligand is a bone-targeting ligand.
88. (New) The method of claim 87 wherein said ligand is a macrocyclic aminophosphonic acid.
89. (New) The method of claim 88, wherein said ligand is 1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid (DOTMP).
90. (New) The method of claim 87, wherein said ligand is selected from the group consisting of ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, hydroxyethylethylenediaminetrimethylenephosphonic acid, nitrilotrimethylenephosphonic acid, tris(2-aminoethyl)aminehexamethylenephosphonic acid, methylene diphosphonate, hydroxymethylenediphosphonate, hydroxyethylidene diphosphonate, and ethane-1-hydroxy-1,1-diphosphonic acid.
91. (New) The method of claim 90, wherein said ligand is ethylenediaminetetramethylenephosphonic acid.
92. (New) The method of claim 86, wherein said radionuclide is selected from the group consisting of Arsenic-77, Molybdenum-99, Rhodium-105, Lutetium-177, Cadmium-115,

**SECOND SUPPLEMENTAL PRELIMINARY AMENDMENT**

Serial Number: 10/784,476

Filing Date: February 23, 2004

Title: HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION

---

**Page 3**

Docket No: 295.044US3

Antimony-122, Promethium-149, Osmium-193, Gold-198, Thorium-200, Samarium-153, Yttrium-90, Gadolinium-159, Rhenium-186, Rhenium-188, and Holmium-166.

93. (New) The method of claim 89 wherein the ligand-complexed radionuclide is  $^{166}\text{Ho}$ -DOTMP.

94. (New) The method of claim 86 wherein the ligand-complexed radionuclide is administered by injection.

95. (New) The method of claim 86 wherein the ligand is administered by infusion.